Literature DB >> 26134396

A lipid switch unlocks Parkinson's disease-associated ATP13A2.

Tine Holemans1, Danny Mollerup Sørensen1, Sarah van Veen1, Shaun Martin2, Diane Hermans1, Gerdi Christine Kemmer3, Chris Van den Haute4, Veerle Baekelandt5, Thomas Günther Pomorski3, Patrizia Agostinis6, Frank Wuytack1, Michael Palmgren3, Jan Eggermont1, Peter Vangheluwe7.   

Abstract

ATP13A2 is a lysosomal P-type transport ATPase that has been implicated in Kufor-Rakeb syndrome and Parkinson's disease (PD), providing protection against α-synuclein, Mn(2+), and Zn(2+) toxicity in various model systems. So far, the molecular function and regulation of ATP13A2 remains undetermined. Here, we demonstrate that ATP13A2 contains a unique N-terminal hydrophobic extension that lies on the cytosolic membrane surface of the lysosome, where it interacts with the lysosomal signaling lipids phosphatidic acid (PA) and phosphatidylinositol(3,5)bisphosphate [PI(3,5)P2]. We further demonstrate that ATP13A2 accumulates in an inactive autophosphorylated state and that PA and PI(3,5)P2 stimulate the autophosphorylation of ATP13A2. In a cellular model of PD, only catalytically active ATP13A2 offers cellular protection against rotenone-induced mitochondrial stress, which relies on the availability of PA and PI(3,5)P2. Thus, the N-terminal binding of PA and PI(3,5)P2 emerges as a key to unlock the activity of ATP13A2, which may offer a therapeutic strategy to activate ATP13A2 and thereby reduce α-synuclein toxicity or mitochondrial stress in PD or related disorders.

Entities:  

Keywords:  P5-type ATPase; flippase; lysosome; mitochondria; α-synuclein

Mesh:

Substances:

Year:  2015        PMID: 26134396      PMCID: PMC4517210          DOI: 10.1073/pnas.1508220112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  The secretory pathway Ca(2+)-ATPase 1 is associated with cholesterol-rich microdomains of human colon adenocarcinoma cells.

Authors:  Szilvia Baron; Peter Vangheluwe; Maria Rosario Sepúlveda; Frank Wuytack; Luc Raeymaekers; Jo Vanoevelen
Journal:  Biochim Biophys Acta       Date:  2010-04-02

2.  Identification of novel ATP13A2 interactors and their role in α-synuclein misfolding and toxicity.

Authors:  Marija Usenovic; Adam L Knight; Arpita Ray; Victoria Wong; Kevin R Brown; Guy A Caldwell; Kim A Caldwell; Igor Stagljar; Dimitri Krainc
Journal:  Hum Mol Genet       Date:  2012-05-29       Impact factor: 6.150

Review 3.  Phosphatidylinositol-3,5-bisphosphate: no longer the poor PIP2.

Authors:  Cheuk Y Ho; Tamadher A Alghamdi; Roberto J Botelho
Journal:  Traffic       Date:  2011-07-27       Impact factor: 6.215

4.  Phospholipase D activity facilitates Ca2+-induced aggregation and fusion of complex liposomes.

Authors:  R A Blackwood; J E Smolen; A Transue; R J Hessler; D M Harsh; R C Brower; S French
Journal:  Am J Physiol       Date:  1997-04

5.  ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome.

Authors:  Anne Grünewald; Björn Arns; Philip Seibler; Aleksandar Rakovic; Alexander Münchau; Alfredo Ramirez; Carolyn M Sue; Christine Klein
Journal:  Neurobiol Aging       Date:  2012-01-31       Impact factor: 4.673

6.  Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase.

Authors:  Alfredo Ramirez; André Heimbach; Jan Gründemann; Barbara Stiller; Dan Hampshire; L Pablo Cid; Ingrid Goebel; Ammar F Mubaidin; Abdul-Latif Wriekat; Jochen Roeper; Amir Al-Din; Axel M Hillmer; Meliha Karsak; Birgit Liss; C Geoffrey Woods; Maria I Behrens; Christian Kubisch
Journal:  Nat Genet       Date:  2006-09-10       Impact factor: 38.330

7.  Characterization of cellular protective effects of ATP13A2/PARK9 expression and alterations resulting from pathogenic mutants.

Authors:  Jason P Covy; Elisa A Waxman; Benoit I Giasson
Journal:  J Neurosci Res       Date:  2012-07-30       Impact factor: 4.164

8.  Lysosomal dysfunction in neurodegeneration: the role of ATP13A2/PARK9.

Authors:  Marija Usenovic; Dimitri Krainc
Journal:  Autophagy       Date:  2012-05-07       Impact factor: 16.016

9.  CtBP/BARS induces fission of Golgi membranes by acylating lysophosphatidic acid.

Authors:  R Weigert; M G Silletta; S Spanò; G Turacchio; C Cericola; A Colanzi; S Senatore; R Mancini; E V Polishchuk; M Salmona; F Facchiano; K N Burger; A Mironov; A Luini; D Corda
Journal:  Nature       Date:  1999-11-25       Impact factor: 49.962

10.  Zn²⁺ dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation.

Authors:  Taiji Tsunemi; Dimitri Krainc
Journal:  Hum Mol Genet       Date:  2013-12-13       Impact factor: 5.121

View more
  38 in total

1.  Structure/activity relationship of thapsigargin inhibition on the purified Golgi/secretory pathway Ca2+/Mn2+-transport ATPase (SPCA1a).

Authors:  Jialin Chen; Joren De Raeymaecker; Jannik Brøndsted Hovgaard; Susanne Smaardijk; Ilse Vandecaetsbeek; Frank Wuytack; Jesper Vuust Møller; Jan Eggermont; Marc De Maeyer; Søren Brøgger Christensen; Peter Vangheluwe
Journal:  J Biol Chem       Date:  2017-03-06       Impact factor: 5.157

2.  Exacerbation of sensorimotor dysfunction in mice deficient in Atp13a2 and overexpressing human wildtype alpha-synuclein.

Authors:  Emily R Dirr; Osunde R Ekhator; Rachel Blackwood; John G Holden; Eliezer Masliah; Patrick J Schultheis; Sheila M Fleming
Journal:  Behav Brain Res       Date:  2018-02-03       Impact factor: 3.332

Review 3.  Regulation of membrane dynamics by Parkinson's disease-associated genes.

Authors:  Tsuyoshi Inoshita; Changxu Cui; Nobutaka Hattori; Yuzuru Imai
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

4.  An N-terminal Ca2+-binding motif regulates the secretory pathway Ca2+/Mn2+-transport ATPase SPCA1.

Authors:  Jialin Chen; Susanne Smaardijk; Charles-Alexandre Mattelaer; Filip Pamula; Ilse Vandecaetsbeek; Jo Vanoevelen; Frank Wuytack; Eveline Lescrinier; Jan Eggermont; Peter Vangheluwe
Journal:  J Biol Chem       Date:  2019-03-28       Impact factor: 5.157

5.  Simultaneous lipidomic and transcriptomic profiling in mouse brain punches of acute epileptic seizure model compared to controls.

Authors:  Raissa Lerner; Julia M Post; Shane R Ellis; D R Naomi Vos; Ron M A Heeren; Beat Lutz; Laura Bindila
Journal:  J Lipid Res       Date:  2017-12-05       Impact factor: 5.922

6.  Unlocking ATP13A2/PARK9 activity.

Authors:  Shaun Martin; Tine Holemans; Peter Vangheluwe
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

7.  Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).

Authors:  Alejandro Estrada-Cuzcano; Shaun Martin; Teodora Chamova; Matthis Synofzik; Dagmar Timmann; Tine Holemans; Albena Andreeva; Jennifer Reichbauer; Riet De Rycke; Dae-In Chang; Sarah van Veen; Jean Samuel; Ludger Schöls; Thorsten Pöppel; Danny Mollerup Sørensen; Bob Asselbergh; Christine Klein; Stephan Zuchner; Albena Jordanova; Peter Vangheluwe; Ivailo Tournev; Rebecca Schüle
Journal:  Brain       Date:  2017-02       Impact factor: 13.501

8.  ATP13A2 deficiency disrupts lysosomal polyamine export.

Authors:  Sarah van Veen; Shaun Martin; Chris Van den Haute; Veronick Benoy; Joseph Lyons; Roeland Vanhoutte; Jan Pascal Kahler; Jean-Paul Decuypere; Géraldine Gelders; Eric Lambie; Jeffrey Zielich; Johannes V Swinnen; Wim Annaert; Patrizia Agostinis; Bart Ghesquière; Steven Verhelst; Veerle Baekelandt; Jan Eggermont; Peter Vangheluwe
Journal:  Nature       Date:  2020-01-29       Impact factor: 49.962

9.  Inhibition of the Formation of the Spf1p Phosphoenzyme by Ca2.

Authors:  Gerardo R Corradi; Nicolas A Czysezon; Luciana R Mazzitelli; Nicolas Sarbia; Hugo P Adamo
Journal:  J Biol Chem       Date:  2016-02-08       Impact factor: 5.157

Review 10.  Endolysosomal dysfunction in Parkinson's disease: Recent developments and future challenges.

Authors:  Lauren R Kett; William T Dauer
Journal:  Mov Disord       Date:  2016-10       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.